- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: BIIB059 is a fully humanized IgG1, clinical stage CLEC4C (BDCA2) targeting monoclonal antibody. It is being evaluated for ability to reduce release of disease-driving interferons (principally IFN-α) in SLE. BIIB059 was developed by Biogen, based on prior evidence of target engagement and SLE-applicable immunomodulatory efficacy of a humanized mAb against BDCA2 named 24F4A .
1. Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A et al.. (2019)
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
J Clin Invest, 129 (3): 1359-1371. [PMID:30645203]
2. Pellerin A, Otero K, Czerkowicz JM, Kerns HM, Shapiro RI, Ranger AM, Otipoby KL, Taylor FR, Cameron TO, Viney JL et al.. (2015)
Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.
EMBO Mol Med, 7 (4): 464-76. [PMID:25762615]